This disruption has significant implications for cancer therapeutics: by combining BET inhibitors with PARP inhibitors, there is potential not only to sensitize homologous recombination‐proficient tumors but also to overcome resistance to PARPis that may develop over time. Here, DNER is linked to cancer.